DOCSLIB.ORG

Advances in Dental Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advances in Dental Research Advances in Dental Research http://adr.sagepub.com/ The Association Between Immunodeficiency and the Development of Autoimmune Disease J.W. Sleasman ADR 1996 10: 57 DOI: 10.1177/08959374960100011101 The online version of this article can be found at: http://adr.sagepub.com/content/10/1/57 Published by: http://www.sagepublications.com On behalf of: International and American Associations for Dental Research Additional services and information for Advances in Dental Research can be found at: Email Alerts: http://adr.sagepub.com/cgi/alerts Subscriptions: http://adr.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav Downloaded from adr.sagepub.com by guest on July 18, 2011 For personal use only. No other uses without permission. THE ASSOCIATION BETWEEN IMMUNODEFICIENCY AND THE DEVELOPMENT OF AUTOIMMUNE DISEASE J.W. SLEASMAN aradoxically, individuals with primary or acquired immunodeficiency disease have an increased Division of Pediatric Immunology and Allergy incidence of autoimmunity. Human primary University of Florida College of Medicine immunodeficiency disease can be classified as Box 100296, 1600 SW Archer Road P disorders of cell-mediated immunity, humoral immunity, Gainesville, Florida 32610-0296 phagocytic cell function, and the complement system (Barrett and Sleasman, 1990). Cell-mediated and humoral immunity Adv Dent Res 10(l):57-61, April, 1996 comprise the adaptive arm of the immune response, which is antigen-specific and confers immunologic memory. The innate immune response, which is antigen-nonspecific, is Abstract—There is a paradoxical relationship between composed of phagocytic cells and the inflammatory peptides. immunodeficiency diseases and autoimmunity. While not all Not all individuals with inherited immunodeficiency develop individuals with immunodeficiency develop autoimmunity, autoimmunity, nor are all individuals with autoimmune nor are all individuals with autoimmunity immunodeficient, disease immunodeficient. Defects within particular defects within certain components of the immune system components of the immune response carry a higher risk for carry a high risk for the development of autoimmune disease. autoimmune disease than others. An understanding of the Inherited deficiencies of the complement system have a high immune defects that may contribute to the development of incidence of systemic lupus erythematosus (SLE), autoimmune disease provides an insight into the nature of the glomerulonephritis, and vasculitis. Carrier mothers of autoimmune process. children with chronic granulomatous disease, an X-linked defect of phagocytosis, often develop discoid lupus. Several SPECIFIC IMMUNODEFICIENCY DISORDERS antibody deficiencies are associated with autoimmune ASSOCIATED WITH AUTOIMMUNITY disease. Autoimmune cytopenias are commonly observed in individuals with selective IgA deficiency and common The most commonly observed association between disorders variable immune deficiency. Polyarticular arthritis can be of innate immunity and an increased risk for the development seen in children with X-linked agammaglobulinemia. of autoimmunity is in individuals with inherited defects in Combined cellular and antibody deficiencies, such as the complement cascade (Frank, 1995). Low serum Wiskott-Aldrich syndrome, carry an increased risk for complement levels found in patients with autoimmune juvenile rheumatoid arthritis and autoimmune hemolytic disease generally reflect increased consumption of anemia. Several hypothetical mechanisms have been complement proteins as a result of immune complex- proposed to explain the associations between autoimmunity mediated inflammation. Clinical manifestations of the and immunodeficiency. Immunologic defects may result in a inherited deficiencies of complement components include failure to exclude microbial antigens, resulting in chronic both an increased incidence of infection and autoimmunity. immunologic activation and autoimmune symptoms. There The complement cascade can be organized into three may be shared genetic factors, such as common HLA alleles, components: the classical pathway, initiated by the binding which predispose an individual to both autoimmunity and of Cl to immunoglobulin Fc receptor; the alternative immunodeficiency. Defects within one component of the pathway, initiated by microbial proteins binding to C3 and immune system may alter the way a pathogen induces an the membrane attack complex; and the final common immune response and lead to an inflammatory response pathway, consisting of C5 through C9, leading to cytolysis directed at self-antigens. An understanding of the (Fig. 1). immunologic defects that contribute to the development of Inherited deficiencies in the components of the classic autoimmunity will provide an insight into the pathogenesis of cascade carry with them a risk for the development of the autoimmune process. systemic lupus erythematosus (SLE), anaphylactoid purpura, and juvenile arthritis. Though rare, nearly 85% of patients Key words: Autoimmunity, immunodeficiency, T-cells, reported to have homozygous C4 deficiency have clinical antibody, complement. manifestations of autoimmunity. Approximately one-half of the individuals with symptomatic C2 deficiency have autoimmune disease (Hauptmann et al., 1988). Recurrent This was presented at the Conference on Oral and Ocular infections are uncommon in C2 deficiency compared with Manifestations of Autoimmune Diseases, January 20-21, other complement disorders, but an increased incidence of 1995, at the University of Florida, Gainesville. bacterial pneumonia, meningitis, and sepsis has been 57 Downloaded from adr.sagepub.com by guest on July 18, 2011 For personal use only. No other uses without permission. 58 SLEASMAN ADV DENT RES APRIL 1996 COMPLEMENT DEFICIENCIES organisms results in granuloma formation. In this way, the Classical immune response compensates for the defect in leukocyte function. While autoimmunity has not been reported in C1 Ag/Antibody Complex Autoimmunity affected male children, the genetic defect is associated with a C1 INH HANE SLE, GN, HSP high incidence of discoid lupus erythematosus (DLE) in C2 carrier mothers (Humbert et al., 1976). Superoxide C3- C3b C56789 membrane attack complex generation in carrier mothers is reduced but not absent. .. * - Cytolysis Studies of women with DLE who are not CGD carriers Pyogeimytmec tion Neissenal Infections indicate that leukocyte bactericidal activity is generally Autoimmunity C3,B,D,P normal (Humbert et al, 1976). Defects of adaptive immunity consist primarily of disorders of T-cell and B-cell function. Alternative Autoimmunity is uncommon in patients with pure T-cell immunodeficiency (Rosen, 1987). Children with X-linked Fig. 1—Complement deficiencies and their association with severe combined immunodeficiency exhibit T-cell maturation infection and autoimmunity. The classic pathway is activated arrest within the thymus (Sleasman et al, 1994). B-cell by antigen/antibody complexes binding to Cl. Loss of Cl numbers are normal, and immunoglobulin secretion can inhibitor {Cl INH) leads to Hereditary Angioneurotic Edema occur in the presence of normal T-cell help. Although this is (HANE). Defects in components of the classic pathway carry the most common form of human SCID, autoimmunity has an increased risk of SLE, glomerulonephritis, and HSP. not been reported in these patients, perhaps a result of early Deficiencies in the alternative pathway are generally treatment with bone marrow transplantation or death in early associated with recurrent infections with pyogenic bacteria. infancy due to infection. While opportunistic infections are a Defects within the components of the membrane attack prominant feature of both adults and children with idiopathic complex carry a risk of neisserial infections and autoimmune or congenital CD4+ T lymphocytopenia, autoimmune disease nephritis has not been associated with this newly described immunodeficiency of CD4+ T lymphocytes (Sleasman et al, reported. A deficiency of Cl inhibitor results in uncontrolled 1990; Duncan et al, 1993; Ho et al, 1993; Smith et al, activation of the classic pathway components and 1993; Spira et al, 1993). In contrast to purely T-cell consumption of C2 and C4. This deficiency leads to recurrent deficiencies, defects in immunoregulatory peptides involved episodes of angioedema of the viscera, soft tissues, and in cell-to-cell interactions are commonly associated with airway, and a high risk of SLE, Crohn's disease, and autoimmune disease. Children with Wiskott-Aldrich Sjogren's syndrome (Brickman et al, 1986a,b). Syndrome, an X-linked immunodeficiency characterized by Defects in the alternative complement pathway are more low expression of sialophorin (CD43), demonstrated a high commonly associated with recurrent pyogenic infections, incidence of Coombs-positive hemolytic anemia, juvenile particularly infections with Neisseria meningitidis and rheumatoid arthritis, and severe eczema (Amman and Hong, Streptococcus pneumoniae; SLE, systemic vasculitis, and 1989). glomerulonephritis have been reported in 15 to 20% of Unlike T-cell defects, humoral immunodeficiencies carry patients with C3 deficiency (Borzy et al, 1988). Cytolysis by a high risk of autoimmunity. Children with X-linked terminal complement components (C5 through C9) are agammaglobulinemia have little detectable immunoglobulin important in host defense against Gram-negative organisms, production due to a
Load more

Recommended publications
  • Khan CV 9-4-20
    CURRICULUM VITAE DAVID A. KHAN, MD University of Texas Southwestern Medical Center 5323 Harry Hines Boulevard Dallas, TX 75390-8859 (214) 648-5659 (work) (214) 648-9102 (fax) [email protected] EDUCATION 1980 -1984 University of Illinois, Champaign IL; B.S. in Chemistry, Magna Cum Laude 1984 -1988 University of Illinois School of Medicine, Chicago IL; M.D. 1988 -1991 Good Samaritan Medical Center, Phoenix AZ; Internal Medicine internship & residency 1991-1994 Mayo Clinic, Rochester MN; Allergy & Immunology fellowship PROFESSIONAL EXPERIENCE 1994 -2001 Assistant Professor of Internal Medicine, UT Southwestern 1997 -1998 Co-Director, Allergy & Immunology Training Program 1998 - Director, Allergy & Immunology Training Program 2002- 2008 Associate Professor of Internal Medicine, UT Southwestern 2008-present Professor of Medicine, UT Southwestern AWARDS/HONORS 1993 Allen & Hanburys Respiratory Institute Allergy Fellowship Award 1993 Von Pirquet Award 2001 Outstanding Teacher 2000-2001 UTSW Class of 2003 2004 Outstanding Teacher 2003-2004 UTSW Class of 2006 2005 Outstanding Teacher 2004-2005 UTSW Class of 2007 2006 Daniel Goodman Lectureship, ACAAI meeting 2007 Most Entertaining Teacher 2006-2007 UTSW Class of 2009 2008 Stanislaus Jaros Lectureship, ACAAI meeting 2009 Outstanding Teacher 2007-2008 UTSW Class of 2010 2011 John L. McGovern Lectureship, ACAAI meeting 2012 I. Leonard Bernstein Lecture, ACAAI meeting 2014 Distinguished Fellow, ACAAI meeting 2015 Elliot F. Ellis Memorial Lectureship, AAAAI meeting 2015 Bernard Berman Lectureship,
    [Show full text]
  • Newborn Screening for Severe Combined Immunodeficiency And
    Newborn screening for SCID and related forms of Primary Immunodeficiency Michael Keller, MD Division of Allergy and Immunology Aims To review the epidemiology and possible presentations of primary immunodeficiency disorders. To learn about the TREC newborn screening assay, and what to do with a positive result. Speaker Disclosures No disclosures to declare. Case: 10 month old girl Ex FT infant, poor weight and chronic diarrhea since 2 months of age. No prior known infections, negative FH. Initial workup CBC: CMP: Na: 135 WBC: 5.6 K: 3.9 Hb: 11.3 Cl: 104 Hct: 34.1 CO2: 24 MCV: 79.1 BUN: 4 Plt: 386 Cr: 0.2 ANC: 2055 Glu: 70 Total protein: 4.9 ALC: 3102 Albumin: 3.0 Eos: 0.2% Alk Phos: 126 Monos: 6.9% ALT: 84 AST: 87 Phos: 4.8 Mg: 2.3 GGT: 17 Differential . Primary GI disease . IBD, allergic enterocolitis, . GI channelopathy . Metabolic disorder or CF . Newborn screening catches many but not all . Chronic infection . HIV . Immune disorder Further testing • Stool testing: negative for norovirus, enterovirus, parechovirus, adenovirus, O&P, culture • Negative CMV, EBV PCRs (blood) • Normal fecal elastase (434) • Positive Rotavirus Antigen EIA Further testing Hypogammaglobulinemia No vaccine responses Further testing Lymphocyte Flow Cytometry Marker Value Normal range (cells/mcl) (cells/mcl) CD3+ (T-cells) 242 1600-6700 CD3/CD4+ 86 1000-4600 CD3/CD8+ 15 400-2100 CD4/CD45RA+ 61 500-1100 CD4/CD45RO+ 57 150-600 CD16/56+, CD3- (NK cells) 223 200-1200 CD19+ (B-cells) 1735 600-2700 Profound T-cell Lymphocytopenia Diagnosis Dx: Severe combined immunodeficiency Epidemiology: Primary immunodeficiency Over 200+ known congenital immunologic defects • In total, primary immunodeficiency is thought to occur as frequent as 1 in 5000.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Immune Checkpoint Blockade in Cancer Therapy Michael A
    Published Ahead of Print on January 20, 2015 as 10.1200/JCO.2014.59.4358 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.4358 JOURNAL OF CLINICAL ONCOLOGY REVIEW ARTICLE Immune Checkpoint Blockade in Cancer Therapy Michael A. Postow, Margaret K. Callahan, and Jedd D. Wolchok All authors: Memorial Sloan Kettering Cancer Center and Weill Cornell Medi- ABSTRACT cal College, New York, NY. Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte–associated Published online ahead of print at www.jco.org on January 20, 2015. antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab Authors’ disclosures of potential (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced conflicts of interest are found in the article online at www.jco.org. Author melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a contributions are found at the end of variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 this article. blockade is associated with a unique pattern of adverse events called immune-related adverse Corresponding author: Jedd D. events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches Wolchok, MD, PhD, Memorial Sloan involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they Kettering, Cancer Center, 1275 York enhance the efficacy of either approach alone.
    [Show full text]
  • Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML
    Published OnlineFirst February 10, 2020; DOI: 10.1158/0008-5472.CAN-19-2175 CANCER RESEARCH | CONVERGENCE AND TECHNOLOGIES Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML Tom Hahnel€ 1, Christoph Baldow1,Joelle€ Guilhot2, Francois¸ Guilhot2, Susanne Saussele3, Satu Mustjoki4,5, Stefanie Jilg6, Philipp J. Jost6, Stephanie Dulucq7, Francois-Xavier¸ Mahon8, Ingo Roeder1,9, Artur C. Fassoni10, and Ingmar Glauche1 ABSTRACT ◥ Recent clinicalfindings in patients with chronic myeloid leukemia a third class of patients that maintained TFR only if an optimal (CML) suggest that the risk of molecular recurrence after stopping balance between leukemia abundance and immunologic activation tyrosine kinase inhibitor (TKI) treatment substantially depends on was achieved before treatment cessation. Model simulations further an individual's leukemia-specific immune response. However, it is suggested that changes in the BCR-ABL1 dynamics resulting from still not possible to prospectively identify patients that will remain in TKI dose reduction convey information about the patient-specific treatment-free remission (TFR). Here, we used an ordinary differ- immune system and allow prediction of outcome after treatment ential equation model for CML, which explicitly includes an cessation. This inference of individual immunologic configurations antileukemic immunologic effect, and applied it to 21 patients with based on treatment alterations can also be applied to other cancer CML for whom BCR-ABL1/ABL1 time courses had been quantified types in which the endogenous immune system supports mainte- before and after TKI cessation. Immunologic control was concep- nance therapy, long-term disease control, or even cure. tually necessary to explain TFR as observed in about half of the patients.
    [Show full text]
  • Evidence for Systemic Immune System Alterations in Sporadic Amyotrophic Lateral Sclerosis (Sals)
    Journal of Neuroimmunology 159 (2005) 215–224 www.elsevier.com/locate/jneuroim Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS) Rongzhen Zhanga, Ron Gascona, Robert G. Millerb, Deborah F. Gelinasb, Jason Massb, Ken Hadlockc, Xia Jinc, Jeremy Reisa, Amy Narvaeza, Michael S. McGratha,* aUniversity of California, San Francisco, San Francisco General Hospital, 995 Potrero Avenue, Building 80, Ward 84, Box 0874, San Francisco, CA 94110, USA bCalifornia Pacific Medical Center, San Francisco, CA 94115, USA cPathologica LLC, Burlingame, CA 94010, USA Received 12 February 2004; received in revised form 7 September 2004; accepted 12 October 2004 Abstract Sporadic amyotrophic lateral sclerosis (sALS) is a progressive neuroinflammatory disease of spinal cord motor neurons of unclear etiology. Blood from 38 patients with sALS, 28 aged-match controls, and 25 Alzheimer’s disease (AD) patients were evaluated and activated monocyte/macrophages were observed in all patients with sALS and AD; the degree of activation was directly related to the rate of sALS disease progression. Other parameters of T-cell activation and immune globulin levels showed similar disease associated changes. These data are consistent with a disease model previously suggested for AD, wherein systemic immunologic activation plays an active role in sALS. D 2004 Elsevier B.V. All rights reserved. Keywords: Amyotrophic lateral sclerosis (ALS); Alzheimer’s disease (AD); Motor neuron disease; Immune activation; Monocyte/macrophage 1. Introduction 1995; Fray et al., 1998), and autoimmunity (Appel et al., 1993). In addition, several recent studies have suggested Amyotrophic lateral sclerosis (ALS) is a devastating that the immune system may be actively involved in the neurological disease characterized by gradual degeneration disease process of ALS, with observations of activated of spinal cord motor neuron cells leading to progressive microglia, IgG deposits, and dysregulation of cytokine weakness, paralysis of muscle and death.
    [Show full text]
  • Current Perspectives on Primary Immunodeficiency Diseases
    Clinical & Developmental Immunology, June–December 2006; 13(2–4): 223–259 Current perspectives on primary immunodeficiency diseases ARVIND KUMAR, SUZANNE S. TEUBER, & M. ERIC GERSHWIN Division of Rheumatology, Allergy and Clinical Immunology, Department of Internal Medicine, University of California at Davis School of Medicine, Davis, CA, USA Abstract Since the original description of X-linked agammaglobulinemia in 1952, the number of independent primary immunodeficiency diseases (PIDs) has expanded to more than 100 entities. By definition, a PID is a genetically determined disorder resulting in enhanced susceptibility to infectious disease. Despite the heritable nature of these diseases, some PIDs are clinically manifested only after prerequisite environmental exposures but they often have associated malignant, allergic, or autoimmune manifestations. PIDs must be distinguished from secondary or acquired immunodeficiencies, which are far more common. In this review, we will place these immunodeficiencies in the context of both clinical and laboratory presentations as well as highlight the known genetic basis. Keywords: Primary immunodeficiency disease, primary immunodeficiency, immunodeficiencies, autoimmune Introduction into a uniform nomenclature (Chapel et al. 2003). The International Union of Immunological Societies Acquired immunodeficiencies may be due to malnu- (IUIS) has subsequently convened an international trition, immunosuppressive or radiation therapies, infections (human immunodeficiency virus, severe committee of experts every two to three years to revise sepsis), malignancies, metabolic disease (diabetes this classification based on new PIDs and further mellitus, uremia, liver disease), loss of leukocytes or understanding of the molecular basis. A recent IUIS immunoglobulins (Igs) via the gastrointestinal tract, committee met in 2003 in Sintra, Portugal with its kidneys, or burned skin, collagen vascular disease such findings published in 2004 in the Journal of Allergy and as systemic lupus erythematosis, splenectomy, and Clinical Immunology (Chapel et al.
    [Show full text]
  • Prevalence and Pathogenicity of Autoantibodies in Patients with Idiopathic CD4 Lymphopenia
    Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia Ainhoa Perez-Diez, … , Richard Siegel, Irini Sereti J Clin Invest. 2020;130(10):5326-5337. https://doi.org/10.1172/JCI136254. Clinical Medicine Autoimmunity Immunology Graphical abstract Find the latest version: https://jci.me/136254/pdf CLINICAL MEDICINE The Journal of Clinical Investigation Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia Ainhoa Perez-Diez,1 Chun-Shu Wong,1 Xiangdong Liu,1 Harry Mystakelis,1 Jian Song,2 Yong Lu,2 Virginia Sheikh,1 Jeffrey S. Bourgeois,1 Andrea Lisco,1 Elizabeth Laidlaw,1 Cornelia Cudrici,3 Chengsong Zhu,4 Quan-Zhen Li,4,5 Alexandra F. Freeman,6 Peter R. Williamson,7 Megan Anderson,1 Gregg Roby,1 John S. Tsang,2,8 Richard Siegel,3 and Irini Sereti1 1HIV Pathogenesis Section, Laboratory of Immunoregulation, and 2Multiscale Systems Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), and 3Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA. 4Microarray Core Facility and 5Department of Immunology and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 6Laboratory of Clinical and Molecular Immunology and 7Translational Mycology Section, Laboratory of Clinical and Molecular Immunology, NIAID, and 8Trans-NIH Center for Human Immunology, NIH, Bethesda, Maryland, USA. BACKGROUND. Idiopathic CD4 lymphopenia (ICL) is defined by persistently low CD4+ cell counts (<300 cells/μL) in the absence of a causal infection or immune deficiency and can manifest with opportunistic infections. Approximately 30% of ICL patients develop autoimmune disease.
    [Show full text]
  • Patient & Family Handbook
    Immune Deficiency Foundation Patient & Family Handbook For Primary Immunodeficiency Diseases This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SIXTH EDITION COPYRIGHT 1987, 1993, 2001, 2007, 2013, 2019 IMMUNE DEFICIENCY FOUNDATION Copyright 2019 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. The Immune Deficiency Foundation Patient & Family Handbook may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA; or by telephone at 800-296-4433. Immune Deficiency Foundation Patient & Family Handbook For Primary Immunodeficiency Diseases 6th Edition The development of this publication was supported by Shire, now Takeda. 110 West Road, Suite 300 Towson, MD 21204 800.296.4433 www.primaryimmune.org [email protected] Editors Mark Ballow, MD Jennifer Heimall, MD Elena Perez, MD, PhD M. Elizabeth Younger, Executive Editor Children’s Hospital of Philadelphia Allergy Associates of the CRNP, PhD University of South Florida Palm Beaches Johns Hopkins University Jennifer Leiding,
    [Show full text]
  • Idiopathic CD4 T Cell Lymphocytopenia: a Case of Overexpression of PD-1/PDL-1 and CTLA-4
    Case Report Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4 Gaurav Kumar 1,2,* , Heidy Schmid-Antomarchi 2 , Annie Schmid-Alliana 2 , Michel Ticchioni 2 and Pierre-Marie Roger 2,3,4,5 1 Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA 2 Unité 576, Institut National de la Santé et de la Recherche Médicale, Hôpital de l’Archet I, 151 Route de Saint-Antoine, 06200 Nice, France; [email protected] (H.S.-A.); [email protected] (A.S.-A.); [email protected] (M.T.); [email protected] (P.-M.R.) 3 Laboratoire d’Immunologie, Hôpital de l’Archet, Centre Hospitalier Universitaire de Nice, 151 Route de Saint-Antoine, 06200 Nice, France 4 Infectiologie, Centre Hospitalier Universitaire de la Guadeloupe, Pointe-à-Pitre/Abymes, Route de Chauvel, Les Abymes, 97139 Guadeloupe, France 5 Faculté de Médecine, Université des Antilles, 97157 Pointe-à-Pitre, France * Correspondence: [email protected]; Tel.: +1-405-271-2907 Abstract: Idiopathic CD4 T cell lymphocytopenia (ICL) is a rare entity characterized by CD4 T cell count of <300 cells/mm3 along with opportunistic infection for which T cell marker expression remains to be fully explored. We report an ICL case for which T lymphocyte phenotype and its costimulatory molecules expression was analyzed both ex vivo and after overnight stimulation through CD3/CD28. The ICL patient was compared to five healthy controls. We observed higher expression of inhibitory molecules PD-1/PDL-1 and CTLA-4 on CD4 T cells and increased regulatory Citation: Kumar, G.; T cells in ICL, along with high activation and low proliferation of CD4 T cells.
    [Show full text]
  • Absolute Lymphocyte Count Is a Prognostic Marker in Covid-19: a Retrospective Cohort Review
    Received: 12 May 2020 | Revised: 26 May 2020 | Accepted: 21 June 2020 DOI: 10.1111/ijlh.13288 ORIGINAL ARTICLE Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review Jason Wagner1 | Andrew DuPont2 | Scott Larson2 | Brooks Cash2 | Ahmad Farooq2,3 1Department of Internal Medicine, University of Texas Health Science Center at Abstract Houston, Houston, TX, USA Introduction: Prognostic factors are needed to aid clinicians in managing Covid-19, 2 Department of Internal Medicine, Division a respiratory illness. Lymphocytopenia has emerged as a simply obtained laboratory of Gastroenterology, Hepatology and Nutrition, University of Texas Health value that may correlate with prognosis. Science Center at Houston, Houston, TX, Methods: In this article, we perform a retrospective cohort review study on patients USA 3Department of Internal Medicine, Division admitted to one academic hospital for Covid-19 illness. We analyzed basic demo- of Gastroenterology and Hepatology, Duke graphic, clinical, and laboratory data to understand the relationship between lym- University, Durham, NC, USA phocytopenia at the time of hospital admission and clinical outcomes. Correspondence Results: We discovered that lymphocyte count is lower (P = .01) and lymphocytope- Ahmad Farooq, Department of Internal Medicine, Division of Gastroenterology, nia more frequent by an odds ratio of 3.40 (95% CI: 1.06-10.96; P = .04) in patients Hepatology and Nutrition, University of admitted to the Intensive Care Unit (ICU), a marker of disease severity, relative to Texas Health Science Center at Houston, 6431 Fannin, MSB 1.150. Houston, TX those who were not. We additionally find that patients with lymphocytopenia were 77030, USA.
    [Show full text]
  • M. Kansasii Pulmonary Disease in Idiopathic CD4+ T-Lymphocytopenia
    Eur Respir J, 1996, 9, 1754–1756 Copyright ERS Journals Ltd 1996 DOI: 10.1183/09031936.96.09081754 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 CASE STUDY M. Kansasii pulmonary disease in idiopathic CD4+ T-lymphocytopenia G. Anzalone*, M. Cei**, A. Vizzaccaro+, B. Tramma*, A. Bisetti† M. Kansasii pulmonary disease in idiopathic CD4+ T-lymphocytopenia. G. Anzalone, *Centro Cardiorespiratorio I.N.A.I.L., Firenze, M. Cei, A. Vizzaccaro, B. Tramma, A. Bisetti. ERS Journals Ltd 1996. Italy. **Centro Trasfusionale Marine Militare, ABSTRACT: Cases of patients with markedly depressed CD4+ T-lymphocyte counts, La Spezia, Italy. +Reparto I^Medicina Ospe- with or without opportunistic infections, in the absence of any evidence of human dale Principale Marina Militare, La Spezia, Italy. +I^Clinica Tisiopneumologica Uni- immunodeficiency virus (HIV) have been described in recent years. In 1992, the versità di Roma, Italy. definition of "idiopathic CD4+ T-lymphocytopenia" was formulated by the Centers for Disease Control and Prevention (CDC) of Atlanta (USA). Correspondence: G. Anzalone, Centro Cardio- respiratorio I.N.A.I.L., Via Delle Porte The present case illustrates the occurrence of an unexplained Mycobacterium Nuove 61, 50144 - Firenze, Italy kansasii pneumonia in a white HIV-negative subject with a persistent depletion of CD4+ T-lymphocytes and suppression of cell-mediated immunity. Keywords: Human immunodeficiency idiopathic CD4+ T-lymphocytopenia To our knowledge, this is the first observation of idiopathic CD4+ T-lymphocyto- M. Kansasii penia with pulmonary mycobacteriosis due to Mycobacterium kansasii, and the sixth Mycobacteriosis case of this kind of immunodeficiency described in Italy. Received: August 25 1995 Eur Respir J., 1996, 9, 1754–1756.
    [Show full text]